Research programme: neurodegenerative disorder therapeutics - United Neuroscience

Drug Profile

Research programme: neurodegenerative disorder therapeutics - United Neuroscience

Alternative Names: Alpha-synuclein vaccine - United Neuroscience; Anti-tau vaccine - United Neuroscience; UB 312

Latest Information Update: 23 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator United Neuroscience
  • Class Peptide vaccines; Synthetic vaccines; Vaccines
  • Mechanism of Action Alpha-synuclein modulators; Tau protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Neurodegenerative disorders

Most Recent Events

  • 16 Apr 2018 United Neuroscience and Lee Goldstein Laboratory agree to research tau-targeted therapeutics for Chronic traumatic encephalopathy
  • 11 Apr 2018 United Neuroscience and the University of Texas Southwestern Medical Center agree to co-develop therapeutics for Alzheimer's and other Neurodegenerative diseases
  • 22 Mar 2018 United Neuroscience and CNRS agree to co-develop therapeutics for Parkinson's disease and other Neurodegenerative disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top